Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-chou, Suntou-gun, Shizuoka 411-8777, Japan.
Anticancer Res. 2013 Aug;33(8):3279-84.
Patients harboring sensitive epidermal growth factor receptor (EGFR) mutations show a dramatic response to treatment with EGFR tyrosine kinase inhibitors (TKIs). However, there have been no clinical reports in lung cancer patients that compare the time-to-response between radiotherapy and EGFR-TKIs.
We reviewed 17 and 32 consecutive patients with inoperable stage III/IV NSCLC who harbored sensitive EGFR mutations and who were treated with thoracic radiotherapy with or without chemotherapy and EGFR-TKIs, respectively.
There were statistically significant differences in time-to-partial response (PR) with regard to the treatment modalities (radiotherapy vs. EGFR-TKIs, median 57 days vs. 22 days, log-rank test, p=0.008).
EGFR-TKIs elicit tumor shrinkage earlier than does radiotherapy in patients with a sensitive EGFR mutation, suggesting that EGFR-TKIs may be useful for early symptom improvement in these patients.
携带敏感表皮生长因子受体（EGFR）突变的患者对 EGFR 酪氨酸激酶抑制剂（TKI）治疗有显著反应。然而，在肺癌患者中，还没有关于放疗和 EGFR-TKIs 之间反应时间的临床报告进行比较。
我们回顾了 17 例和 32 例不能手术的 III/IV 期 NSCLC 患者，他们携带敏感的 EGFR 突变，分别接受了胸部放疗联合或不联合化疗和 EGFR-TKIs 治疗。
治疗方式（放疗与 EGFR-TKIs）与部分缓解（PR）时间有显著差异（放疗组中位时间 57 天，EGFR-TKIs 组中位时间 22 天，对数秩检验，p=0.008）。
在携带敏感 EGFR 突变的患者中，EGFR-TKIs 引起肿瘤缩小的时间早于放疗，这表明 EGFR-TKIs 可能对这些患者的早期症状改善有用。
